Table 2.

Characteristics of case–control studies included in XPD Lys751Gln (A429C) polymorphisms and breast cancer risk

First author	Year	Country	Ethnicity	Genotyping methods	Source of Control	Cases			Controls
						AA	AC	CC	AA	AC	CC
Samson	2010	India	Asian	TaqMan	PB	107	102	41	235	214	51
Jelonek	2010	Poland	Caucasian	PCR-RFLP	PB	54	47	22	116	128	29
Wang	2010	China	Asian	PCR-RFLP	PB	1136	81	15	1316	96	21
Syamala	2009	India	Asian	PCR-RFLP	HB	148	161	50	247	98	22
Synowiec	2008	Poland	Caucasian	PCR-RFLP	PB	15	24	4	30	17	1
Rajaraman	2008	USA	Caucasian	TaqMan	PB	342	377	120	428	494	158
Makowska	2007	Poland	Caucasian	PCR-RFLP	PB	16	19	57	26	52	32
Kipikasova	2008	Slovak	Caucasian	PCR-RFLP	PB	43	53	18	46	50	17
Shen	2006	USA	Mix	Taqman	PB	63	66	25	74	57	22
Costa	2007	Portugal	Caucasian	PCR-RFLP	PB	127	125	30	331	260	69
Jorgensen	2007	USA	Mix	Taqman	PB	30	175	104	34	159	125
Debniak	2006	Poland	Caucasian	PCR-RFLP	PB	703	850	277	432	547	162
Onay	2006	Canada	Caucasian	Taqman	PB	146	194	58	165	167	40
Mechanic(a)	2006	USA	Caucasian	PCR-RFLP	PB	525	590	158	445	538	150
Mechanic(b)	2006	USA	African-American	PCR-RFLP	PB	415	295	51	393	246	40
Metsola	2005	Finland	Caucasian	PCR-RFLP	PB	147	238	96	155	237	88
Brauch	2004	Germany	Caucasian	PCR-RFLP	PB	224	265	97	264	292	87
Terry	2004	USA	Mix	Taqman	PB	387	513	153	453	498	151
Shi	2004	USA	Caucasian	PCR-RFLP	PB	30	31	8	38	35	6
Tang	2002	USA	Mix	PCR-RFLP	PB	45	42	16	54	46	21

PCR-RFLP PCR-restriction fragment length polymorphism, HB hospital based, PB population based